Agios Pharmaceuticals (NASDAQ:AGIO) pops as FDA review moves price above average target
Agios Pharmaceuticals soared Tuesday after the FDA granted its sickle-cell disease application priority review. Shares pushed through the average Wall Street price target before any official FDA decision.
